AU2001278555A1 - Method for screening peptides for use in immunotherapy - Google Patents

Method for screening peptides for use in immunotherapy

Info

Publication number
AU2001278555A1
AU2001278555A1 AU2001278555A AU7855501A AU2001278555A1 AU 2001278555 A1 AU2001278555 A1 AU 2001278555A1 AU 2001278555 A AU2001278555 A AU 2001278555A AU 7855501 A AU7855501 A AU 7855501A AU 2001278555 A1 AU2001278555 A1 AU 2001278555A1
Authority
AU
Australia
Prior art keywords
iia
class
identifying
peptide
subdominant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278555A
Other languages
English (en)
Inventor
David Alexandre Gross
Kostas Kosmatopoulos
Antonio Scardino
Sophie Tourdot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Gustave Roussy (IGR)
Publication of AU2001278555A1 publication Critical patent/AU2001278555A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
AU2001278555A 2000-07-21 2001-07-20 Method for screening peptides for use in immunotherapy Abandoned AU2001278555A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0009591A FR2812087B1 (fr) 2000-07-21 2000-07-21 Procede de criblage de peptides utilisables en immunotherapie
FR00/09591 2000-07-21
PCT/FR2001/002387 WO2002008716A2 (fr) 2000-07-21 2001-07-20 Procede de criblage de peptides utilisables en immunotherapie

Publications (1)

Publication Number Publication Date
AU2001278555A1 true AU2001278555A1 (en) 2002-02-05

Family

ID=8852782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278555A Abandoned AU2001278555A1 (en) 2000-07-21 2001-07-20 Method for screening peptides for use in immunotherapy

Country Status (11)

Country Link
US (2) US7425606B2 (de)
EP (1) EP1309860B1 (de)
AT (1) ATE378590T1 (de)
AU (1) AU2001278555A1 (de)
CA (1) CA2416761C (de)
DE (1) DE60131413T2 (de)
DK (1) DK1309860T3 (de)
ES (1) ES2296778T3 (de)
FR (1) FR2812087B1 (de)
PT (1) PT1309860E (de)
WO (1) WO2002008716A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6982086B2 (en) 2000-02-04 2006-01-03 Duke University Human immunodeficiency virus immunogenic composition
WO2001060391A1 (en) * 2000-02-15 2001-08-23 Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
EP1752160A3 (de) * 2001-04-06 2007-05-30 Mannkind Corporation Epitop-Sequenzen
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2006120038A2 (en) * 2005-05-09 2006-11-16 Vaxon Biotech Use of native peptides and their optimized derivatives for vaccination
ATE435660T1 (de) * 2005-12-23 2009-07-15 Vaxon Biotech Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
EP1887084A1 (de) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmide mit immunologischer Wirkung
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
JP2014516538A (ja) * 2011-05-26 2014-07-17 ジーニウス バイオテクノロジー インベストメンツ リミテッド ライアビリティ カンパニー 調節された免疫優勢療法
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
AU2287595A (en) * 1994-04-11 1995-10-30 Ixsys, Inc. Class i peptide binding motifs
ATE296444T1 (de) * 1996-03-21 2005-06-15 Circassia Ltd Kryptische peptide und verfahren zu ihrer identifizierung
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US7851591B1 (en) * 1998-10-29 2010-12-14 Dana Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT
WO2001060391A1 (en) * 2000-02-15 2001-08-23 Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie

Also Published As

Publication number Publication date
CA2416761A1 (fr) 2002-01-31
WO2002008716A2 (fr) 2002-01-31
WO2002008716A3 (fr) 2003-02-27
US20090269363A1 (en) 2009-10-29
PT1309860E (pt) 2008-02-25
US7425606B2 (en) 2008-09-16
EP1309860B1 (de) 2007-11-14
DE60131413D1 (de) 2007-12-27
FR2812087B1 (fr) 2007-05-11
ATE378590T1 (de) 2007-11-15
FR2812087A1 (fr) 2002-01-25
CA2416761C (fr) 2013-04-23
DK1309860T3 (da) 2008-03-17
US7976843B2 (en) 2011-07-12
EP1309860A2 (de) 2003-05-14
DE60131413T2 (de) 2008-09-04
US20040072240A1 (en) 2004-04-15
ES2296778T3 (es) 2008-05-01

Similar Documents

Publication Publication Date Title
AU2001278555A1 (en) Method for screening peptides for use in immunotherapy
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
Touloukian et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
Antoniades et al. Human platelet-derived growth factor (PDGF): amino-terminal amino acid sequence
Sheldon et al. Loligomers: design of de novo peptide-based intracellular vehicles.
Fischer Lindahl et al. H2-M3, a full-service class Ib histocompatibility antigen
Hurt et al. A cytosolic protein contains a cryptic mitochondrial targeting signal
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
GB2439474A (en) LI-Key/Antigenic epitope hybrid peptide vaccines
EP0997477A3 (de) MHC-Komplexe und ihre Verwendung
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
BR9813416A (pt) Composições e métodos de nodavìrus recombinante
CA2420350A1 (en) Membrane penetrating peptides and uses thereof
NO995002D0 (no) Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF-<alfa>-molekyler og DNA
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
CA2542104A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
EP2649091A1 (de) Immunrestringierte peptide mit erhöhter wirksamkeit
Posthuma et al. Proteosomal degradation of BCR/ABL protein can generate an HLA-A* 0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated
AP2368A (en) Novel expression vectors and uses thereof.
CA2819978A1 (en) Immune restricted peptides with increased efficacy
CA2344993A1 (en) Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus
Rhodes et al. Isolation and characterization of the cyanogen bromide peptides derived from the human. alpha. 2 (V) collagen chain
WO2022155417A3 (en) Cytolytic t cell immunotherapy for highly pathogenic coronaviruses
PT996636E (pt) Antigenio ha-1
TW581812B (en) Assay for the diagnosis of schizophrenia based on a new peptide